Founded in 2007, Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. As a leader in the renal community, we leverage scientific expertise and commercial capabilities to deliver unique therapeutics to address the complications of kidney disease.   We are located in the biotech hub of Kendall Square in Cambridge, Massachusetts, where we are inspired by our peers and dedicated to working with our partners, patients, advocacy organizations and the broader renal community. We have both a commercially available product, and a late-stage candidate for the potential treatment of anemia due to CKD.